Opening Comments at the American Association for the Advancement of Science (AAAS) consultation on Human Enhancement
By Richard Hayes
| 06. 01. 2006
Mark Frankel asked if we’d share some general perspectives on what we believe to be the major challenges posed as we consider technologies of “enhancement.” I’d like to share the perspective of the Center for Genetics and Society, as well as what we’ve learned about the perspectives of a wide range of Americans and others.
CGS got started following a series of meetings held in 2000 on the social and political implications of the new human genetic technologies. The meetings brought together people concerned about social and economic justice, women’s health and reproductive rights, science and society, environmental protection, and the rights of the disabled.
Those participating became concerned when they learned how rapidly these new technologies were being developed, how profoundly consequential these could be, how thin were the few rules and regulations in place, and how well below the radar screens of both the general public and policy makers all this was.
A major concern was that use of these technologies could greatly exacerbate human inequality, in particular through a revival of eugenic technologies and ideologies, this time...
Related Articles
By Ian Sample, The Guardian | 07.04.2024
Biological models of human embryos that can develop heartbeats, spinal cords and other distinctive features will be governed by a code of practice in Britain to ensure that researchers work on them responsibly.
Made from stem cells, they mimic, to...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...